Late Breaking Abstract Parallel Session 2
Nov
2026
Description
Discover and learn more about the latest advancement and breakthroughs in hepatology that are shaping the future of liver disease.
Presentations
5:00 PM
- 5:15 PM
Convention Center - General Session, Hall A
Seladelpar for Alkaline Phosphatase Normalization in Primary Biliary Cholangitis: Results from the IDEAL Phase III Randomized-Controlled Trial
Cynthia Levy, MD, FAASLD | Abstract Presenter
5:15 PM
- 5:30 PM
Convention Center - General Session, Hall A
Saroglitazar Magnesium Achieves Resolution of Steatohepatitis Without Worsening Fibrosis in Patients with MASH: Results of a Randomized, Placebo-Controlled Phase 2b Trial (EVIDENCES X)
Naga Chalasani, MD, FAASLD | Abstract Presenter
5:30 PM
- 5:45 PM
Convention Center - General Session, Hall A
Efficacy and Safety of an Oral TLR7 Agonist Through 48 Weeks in NAs-Treated Chronic HBV Infection: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial
Hong Tang | Abstract Presenter
5:45 PM
- 6:00 PM
Convention Center - General Session, Hall A
Efficacy and safety of sequential BRII-179, elebsiran, and pegylated interferon alfa therapy in chronic hepatitis B virus infection: end-of-treatment and follow-up results from the phase 2 ENRICH study
Jinlin Hou, MD | Abstract Presenter
6:00 PM
- 6:15 PM
Convention Center - General Session, Hall A
Durability of Functional Cure to AHB-137 Monotherapy in Treatment-Naïve Participants with Chronic Hepatitis B: Long-Term Follow-Up Results of the AB-10-8004 Study
Hao Wang, MD, | Abstract Presenter
6:15 PM
- 6:30 PM
Convention Center - General Session, Hall A
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orziloben (NST-6179) in Adults with Intestinal Failure-Associated Liver Disease (IFALD)
Manpreet Mundi | Abstract Presenter
